{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-014223","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.373027+00:00","generated_at":"2026-06-06T19:44:50.239602+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ResMed Q2 FY2024 revenue $1.16B (+12% YoY); non-GAAP EPS $1.88 (+13%)","bullets":["Revenue $1,162.8M (+12% YoY, +11% constant currency); GAAP op profit down 2%, non-GAAP op profit up 20% to $365.5M.","GAAP diluted EPS $1.42 (-7%); non-GAAP diluted EPS $1.88 (+13%), driven by revenue growth and cost discipline.","Board declared $0.48/share quarterly cash dividend with record date Feb 8, payable March 14.","Resumed share repurchase program; repurchased $50M of common stock during the quarter.","Gross margin contracted 50 bps to 55.6% GAAP; non-GAAP gross margin improved 10 bps to 56.9%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-014223","json":"https://secwatch.observer/filing/0001193125-24-014223.json","markdown":"https://secwatch.observer/filing/0001193125-24-014223.md","text":"https://secwatch.observer/filing/0001193125-24-014223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312524014223/0001193125-24-014223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312524014223/d685328d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:44:50.239602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"676a08f2da36195d134a41fc61df502c14839f20","claim":"RESMED INC reported quarter ended December 31, 2023 results: revenue $1,162.8, net income $208.8, EPS $1.42.","evidence_excerpt":"and Operating Metrics Unaudited; $ in millions, except for per share amounts Three Months Ended December 31, 2023 December 31, 2022 % Change Constant Currency (A) Revenue $ 1,162.8 $ 1,033.7 12 % 11 % Gross margin 55.6 % 56.1 % (1 ) Non-GAAP gross margin (B) 56.9 % 56.8 % — Selling, general, and administrative expenses 222.2 211.7 5 4 Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/943819/000119312524014223/0001193125-24-014223-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended December 31, 2023"},{"label":"Revenue","value":"$1,162.8"},{"label":"Net income","value":"$208.8"},{"label":"EPS","value":"$1.42"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}